Clinical Trial Detail

NCT ID NCT04198766
Title Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Inhibrx, Inc.
Indications

renal cell carcinoma

lung non-small cell carcinoma

transitional cell carcinoma

head and neck squamous cell carcinoma

Advanced Solid Tumor

melanoma

gastric adenocarcinoma

gastroesophageal adenocarcinoma

Therapies

INBRX-106

INBRX-106 + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST